Novavax Inc NVAX:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 9:54 AM EDT
211.14quote price arrow up+22.57 (+11.97%)
Volume
2,466,846
52 week range
76.59 - 331.68

...

Loading . . .
  • Open206.17
  • Day High214.00
  • Day Low202.57
  • Prev Close188.57
  • 52 Week High331.68
  • 52 Week High Date02/09/21
  • 52 Week Low76.59
  • 52 Week Low Date11/10/20

Key Stats

  • Market Cap15.643B
  • Shares Out74.09M
  • 10 Day Average Volume2.93M
  • Dividend-
  • Dividend Yield-
  • Beta1.58
  • YTD % Change90.03

KEY STATS

  • Open206.17
  • Day High214.00
  • Day Low202.57
  • Prev Close188.57
  • 52 Week High331.68
  • 52 Week High Date02/09/21
  • 52 Week Low76.59
  • 52 Week Low Date11/10/20
  • Market Cap15.643B
  • Shares Out74.09M
  • 10 Day Average Volume2.93M
  • Dividend-
  • Dividend Yield-
  • Beta1.58
  • YTD % Change90.03

RATIOS/PROFITABILITY

  • EPS (TTM)-9.25
  • P/E (TTM)-22.82
  • Fwd P/E (NTM)-57.19
  • EBITDA (MRQ)-596.177M
  • ROE (MRQ)-121.19%
  • Revenue (MRQ)919.45M
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)-66.90%
  • Debt To Equity (MRQ)44.29%

EVENTS

  • Earnings Date08/05/2021
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Novavax Inc

There is no recent news for this security.

Profile

MORE
Novavax, Inc. is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases. The Company's product pipeline focuses on a range of infectious diseases with vaccine candidates...
James Young Ph.D.
Chairman
Stanley Erck
President
Rick Crowley
Chief Operating Officer
John Trizzino
Chief Financial Officer
Troy Morgan J.D.
Executive Vice President
Address
21 Firstfield Rd
Gaithersburg, MD
20878-1757
United States